Chandan Healthcare Ltd

Chandan Healthcare Ltd

₹ 207 -2.82%
18 Jun - close price
About

Incorporated in September 2003, Chandan Healthcare Limited runs diagnostic centers in North India with pathology and radiology testing services.[1]

Key Points

Business Profile[1]
Chandan Healthcare Limited operates a diagnostic network in North India that offers pathology and radiology testing services. The company has a presence in Uttar Pradesh, Uttarakhand, and Jaipur (Rajasthan), with a strong network of labs, satellite centers, and collection points

  • Market Cap 505 Cr.
  • Current Price 207
  • High / Low 358 / 184
  • Stock P/E 17.3
  • Book Value 69.9
  • Dividend Yield 0.00 %
  • ROCE 23.3 %
  • ROE 19.9 %
  • Face Value 10.0

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 25.8%

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Debtor days have increased from 82.4 to 114 days.
  • Working capital days have increased from 61.8 days to 111 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2024 Mar 2025 Sep 2025 Dec 2025 Mar 2026
54.64 62.65 67.90 65.01 75.58
45.75 52.41 53.75 53.17 63.15
Operating Profit 8.89 10.24 14.15 11.84 12.43
OPM % 16.27% 16.34% 20.84% 18.21% 16.45%
0.17 2.42 0.84 -1.46 1.13
Interest 1.09 1.30 1.40 1.28 1.80
Depreciation 1.35 2.70 2.46 2.40 2.45
Profit before tax 6.62 8.66 11.13 6.70 9.31
Tax % 30.21% 29.56% 25.79% 24.93% 24.70%
4.20 6.02 7.80 4.54 6.92
EPS in Rs 2.10 2.46 3.19 1.86 2.83
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
120 137 177 230 276
117 128 150 189 224
Operating Profit 2 9 26 41 53
OPM % 2% 7% 15% 18% 19%
0 0 1 2 1
Interest 2 2 3 5 6
Depreciation 2 2 3 7 10
Profit before tax -1 5 21 32 38
Tax % 3% 28% 24% 27% 25%
-1 3 16 24 27
EPS in Rs -0.56 1.68 8.14 9.07 11.07
Dividend Payout % 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 26%
TTM: 20%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 105%
TTM: 32%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 3%
Return on Equity
10 Years: %
5 Years: 22%
3 Years: 26%
Last Year: 20%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 20 20 20 24 24
Reserves 4 7 21 98 147
17 21 36 48 54
41 49 41 40 65
Total Liabilities 82 98 118 211 290
29 33 48 76 101
CWIP 0 0 0 4 12
Investments 6 7 3 1 20
46 58 66 129 156
Total Assets 82 98 118 211 290

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
6 4 1 -29 16
-11 -6 -15 -36 -40
3 2 16 67 21
Net Cash Flow -1 0 2 2 -3
Free Cash Flow -1 -1 -18 -68 -26
CFO/OP 275% 60% 23% -50% 49%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 88 63 59 74 114
Inventory Days 46 71 96 126 92
Days Payable 185 251 102 102 112
Cash Conversion Cycle -51 -117 53 98 95
Working Capital Days -11 -21 -1 75 111
ROCE % 16% 37% 29% 23%

Insights

In beta
Mar 2023 Mar 2024 Sep 2025
Geographic Presence (States)
Number

Log in to view insights

Please log in to see hidden values.

Login
Number of Diagnostic Centres
Number
Total Patient Count
Lakhs
Total Tests Conducted
Lakhs
Number of Collection Centres
Number
Number of Pharmacy Stores
Number
Pathology Tests Offered
Number
Radiology Tests Offered
Number
Revenue per patient
INR

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Mar 2025Sep 2025Dec 2025Mar 2026
49.43% 49.47% 49.47% 49.55%
3.86% 1.11% 0.00% 0.01%
6.32% 5.02% 4.76% 5.03%
40.38% 44.41% 45.78% 45.42%
No. of Shareholders 8971,3071,4641,624

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents